<DOC>
	<DOCNO>NCT00396760</DOCNO>
	<brief_summary>The hypothesis study antifibrinolytic drug aprotinin tranexamic acid equally influence bleeding tendency transfusion requirement patient undergo first time cardiac procedure low risk increase postoperative bleeding.Only patient undergo first time CABG first time aortic valve replacement include study .</brief_summary>
	<brief_title>Comparison Aprotinin Tranexamic Acid Routine Cardiac Surgery</brief_title>
	<detailed_description>Excessive bleeding cardiac surgery serious complication . It expose patient risk allogeneic blood transfusion blood product risk mediastinal re-exploration.Antifibrinolytic drug like aprotinin tranexamic acid proven reduce bleed tendency transfusion requirement cardiac surgery . The efficacy drug proven , especially unspecific proteinase inhibitor aprotinin , however , concern safety high cost drug . There limited head-to-head comparison two drug . In double-blind , prospective , control study efficacy aprotinin tranexamic acid compare . Primary outcome 24 hour postoperative drainage blood loss percentage patient require allogeneic blood transfusion hospital stay . Subgroups patient undergo CABG surgery aortic valve replacement predefined combined separate data analysis.The power study calculate subgroup-analysis . Secondary outcome measurement molecular marker activation hemostasis 5th postoperative day .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Aprotinin</mesh_term>
	<criteria>informed consent Patients undergoing primary CABG Aortic valve replacement surgery Previous sternotomy OPCAB surgery urgent/emergency operation Coumadin treatment previous aprotinin exposure preoperative renal impairment ( Creatinine &gt; 2 mg/dL ) patient refuse blood transfusion inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>cardiac surgery</keyword>
	<keyword>blood transfusion</keyword>
	<keyword>antifibrinolytics</keyword>
	<keyword>aprotinin</keyword>
	<keyword>tranexamic acid</keyword>
</DOC>